Sally Arai

Publications

• H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. Sahaf B, Yang Y, Arai S, Herzenberg LA, Herzenberg LA, Miklos DB. Proc Natl Acad Sci U S A. 2013; 110 (8): 3005-10
• The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Dinner S, Witteles W, Witteles R, Lam A, Arai S, Lafayette R, George TI, Schrier SL, Liedtke M. Br J Haematol. 2013; 161 (3): 367-72
• Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. Varr BC, Liedtke M, Arai S, Lafayette RA, Schrier SL, Witteles RM. J Heart Lung Transplant. 2012; 31 (3): 325-31
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB. Blood. 2012; 119 (25): 6145-54
• Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Bone Marrow Transplant. 2012; 47 (4): 581-8
• A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Chen GL, Arai S, Flowers ME, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB. Blood. 2011; 118 (15): 4070-8
• Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Biol Blood Marrow Transplant. 2011; 17 (11): 1679-87
• Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen. Schaenman JM, Shashidhar S, Rhee C, Wong J, Navato S, Wong RM, Ho DY, Arai S, Johnston L, Brown JM. Biol Blood Marrow Transplant. 2011; 17 (5): 693-702
• Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, Arora M, Weisdorf DJ, Flowers ME, Martin PJ, Palmer J, Jacobsohn D, Pavletic SZ, Vogelsang GB, Lee SJ. Blood. 2011; 118 (15): 4242-9
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Bone Marrow Transplant. 2011; 46 (2): 192-9
• Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. Jones CD, Arai S, Lowsky R, Tyan DB, Zehnder JL, Miklos DB. Br J Haematol. 2010; 150 (5): 637-9
• Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Biol Blood Marrow Transplant. 2010; 16 (8): 1145-54
• Rituximab in hematopoietic cell transplantation. Arai S, Miklos DB. Expert Opin Biol Ther. 2010; 10 (6): 971-82
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Blood. 2009; 114 (5): 1099-109
• Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Cytotherapy. 2008; 10 (6): 625-32
• A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. J Clin Oncol. 2007; 25 (6): 634-41
• Natural killer cells: can they be useful as adoptive immunotherapy for cancer? Arai S, Klingemann H-G. Expert Opin Biol Ther. 2005: 5 163-172
• Association of Foxp3 regulatory gene expression and graft-versus-host disease Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD. Blood. 2004: 104 2187-93
• Poor outcome in steroid refractory GVHD with ATG treatment Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Biol Blood Marrow Transplant. 2002: 8 155-60
• von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM. The Hematology Journal. 2001: 2 292-299